omalizumab + inhaled corticosteroids + long-acting beta 2-adrenergic agonist

Omalizumab + inhaled corticosteroids + long-acting beta 2-adrenergic agonist is a **combination therapy** used for patients with moderate-to-severe allergic asthma whose symptoms are not adequately controlled on inhaled corticosteroids and long-acting beta 2-adrenergic agonists alone. - **Omalizumab** is a recombinant humanized IgG1 monoclonal antibody that binds to free immunoglobulin E (IgE), preventing its interaction with high-affinity receptors (Fc-epsilon-RI) on mast cells, basophils, and eosinophils, thereby interrupting the allergic inflammatory cascade and reducing symptoms[1][2][4][5][6]. - **Inhaled corticosteroids** are synthetic glucocorticoids that bind to and activate the glucocorticoid receptor, exerting anti-inflammatory effects by suppressing cytokine production, reducing airway inflammation, and decreasing hyperresponsiveness. - **Long-acting beta 2-adrenergic agonists** stimulate the beta-2 adrenergic receptor on airway smooth muscle, leading to bronchodilation and sustained improvement in airflow. This regimen is indicated for severe allergic asthma as adjunctive therapy in patients whose asthma is not controlled on maximum inhaled corticosteroid plus long-acting beta-2 agonist therapy[1][4].